- Six wellness peptides win backing from FDA advisory committeeAfter two days of meetings, an FDA advisory committee last week voted to lift restrictions on six popular health and wellness peptides, setting aside FDA staff concerns about a lack of safety and e…Endpoints · 13m ago↗ source
- Yarrow to begin trading as it targets Graves; FDA approves Otsuka's ADHD pillPlus news about Outlook Therapeutics, Gossamer Bio, Apnimed and Entera Bio. 📈 Yarrow closes merger to go public: Yarrow Bioscience is developing an anti-TSHR antibody for Graves’ disease and thy…Endpoints · 1h ago↗ source
- FDA disputes Capricor's claims of Phase 3 success for DMD cell therapyIn briefing documents published Monday ahead of an advisory committee meeting for deramiocel, the FDA disagreed with Capricor's assertion that a Phase 3 trial met its primary outcome measures.